Implementation of an ADME Enabling Selection and Visualization Tool for Drug Discovery

Journal of Pharmaceutical Sciences

Volumn 93, Issue 5, 2004, Pages 1131-1141

  Stoner, Chad L ^a   Gifford, Eric ^a   Stankovic, Charles ^a   Lepsy, Christopher S ^a   Brodfuehrer, Joanne ^a   Prasad, J V N Vara ^a   Surendran, Narayanan ^a  

^a PFIZER INC   (United States)

Author keywords

ADME; Data analysis; HIV; In silico; Spotfire

Indexed keywords

AG 1776; AMIDE; CYTOCHROME P450 3A4; PD 224397; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER PROGRAM; DATA ANALYSIS; DRUG SOLUBILITY; HIGH THROUGHPUT SCREENING; PHARMACEUTICAL ENGINEERING; STRUCTURE ACTIVITY RELATION;

EID: 1942434693     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20020     Document Type: Article

References (14)

1. Avdeef A. 2001. Physicochemical profiling (solubility, permeability, and charge state). Curr Top Med Chem 1:277-351.
2. Mandagere AK, Thompson TN, Hwang KK. 2002. Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45(2):304-311.
3. Stoner CL, Gifford E, Stankovic C, Lepsy C, Erickson E, Surendran N. 2002. The implementation of a Spotfire® solution, an ADME enabling selection tool. AAPS Pharm Sci 4(4), Abstract T3255.
4. Parrott N, Lave T. 2002. Prediction of intestinal absorption: Comparative assessment of Gastro-plus™ and IDEA™. Eur J Pharm Sci 17:51-61.
5. Stilgenbauer L, Surendran N, Reddy A, Michael S, Liu H, Freiwald S, Bobrowski W, Stoner C, Stewart B. 2000. Validation of 24-well plate format for high throughput screening of permeability in Caco-2 cells. AAPS PharmSci 2(2), Abstract 846.
6. Stilgenbauer L, Wang Y, Surendran N, Reddy A, Michael S, Hoffman K, Tripathy S, Liu H, Freiwald S, Heimbach T, Stewart B. 2000. Automation and validation of 24-well plate format for high throughput screening of metabolic stability in microsomes. AAPS PharmSci 2(2), Abstract 147.
7. Kibbey CE, Poole AK, Robinson B, Jackson JD, Durham D. 2001. An integrated process for measuring the physicochemical properties of drug candidates in a preclinical discovery environment. J Pharm Sci 90:1164-1175.
8. Wang Y, Reyner E, Heimbach T, Stilgenbauer L, Gifford E, Stoner CL, Surendran N, Stewart BH. 2001. Risk assessment of CYP3A4 inhibition potential in drug discovery. Pharmaceutical Congress of the Americas. March 2001.
9. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25.
10. Lipinski CA. 2000. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235-249.
11. Waterbeemd H, Smith DA, Beaumont K, Walker DK. 2001. Property-based design: Optimization of drug absorption and pharmacokinetics. J Med Chem 44:1313-1333.
12. Surendran N, Chan OH, Whittico MT, Stoner CL, Stewart BH. 1999. Estimated dose absorbed (EDA): Concept and its application to the early drug discovery setting. Pharmacokinetics, Dynamics and Metabolism Dept. Parke-Davis Pharmaceutical Research Division, Warner Lambert Co. Ann Arbor, MI. AAPS meeting, New Orleans, LA, Nov. 1999.
13. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, McIntyre F, Rance DJ, Wastall P. 1997. The Prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmcol Exp Ther 283:46-58.
14. Spotfire® DecisionSite product release information: DecisionSite analytic application. 2002. Somerville, MA: Spotfire Corporation.